Artificial intelligence (AI) has transformed scientific research and innovation, yet as previously discussed, the Polanyi Paradox remains a significant obstacle to using AI to generate creative solutions or breakthrough...more
On January 6, 2025, the U.S. Food and Drug Administration (FDA) released draft guidance titled Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products...more
1/16/2025
/ Artificial Intelligence ,
Clinical Trials ,
Compliance ,
Digital Health ,
Draft Guidance ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
Machine Learning ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Regulatory Requirements ,
Risk Management ,
Trade Secrets